Studies in animal models have shown an anorexigenic action of GIP receptor agonism [36] and a recent phase 1 clinical trial with a long-acting GIP RA found that repeated dosing for 4 weeks induced modest WL (−1.9 to −3.1 kg vs. −0.4 kg with placebo) in people with T2D, without delay in gastric emptying or nausea and vomiting [37]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.